Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T16:52:38.144Z.
Calculation as of: 2026-10-06T16:52:38.144Z.
Quote observation: 2026-10-06T16:50:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
PE RATIO
N/A
Obsidian Therapeutics Inc.
Market Cap
$14.10M
PE Ratio
N/A
| NAME | MARKET CAP | PE RATIO |
|---|---|---|
| Obsidian Therapeutics Inc. (OBX) | $14.10M | N/A |
| Sintx Technologies, Inc. (SINT)vs › | $13.92M | N/A |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.79M | N/A |
| Vyome Holdings, Inc. (HIND)vs › | $13.66M | N/A |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.57M | N/A |
| IN8bio, Inc. (INAB)vs › | $13.62M | N/A |
| Optimi Health Corp. (OPTH)vs › | $13.33M | N/A |
| Pasithea Therapeutics Corp. (KTTA)vs › | $14.98M | N/A |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.90M | N/A |
| Passage Bio, Inc. (PASG)vs › | $12.88M | N/A |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
